Onercept. Serono.
Onercept is a recombinant human soluble p55 tumor necrosis factor binding protein under development by Serono for the potential treatment of a number of disorders, including Crohn's disease, psoriasis and psoriatic arthritis. In March 2002, phase II trials were ongoing for these indications, and in February 2003, Serono expected phase III trials in psoriatic arthritis to commence in the second half of 2003.
Nikas
Spyros N
SN
Department of Internal Medicine, Division of Rheumatology, Medical School, University of Ioannina, Ioannina 45110, Greece. snnikas@yahoo.com
Drosos
Alexandros A
AA
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D002352:Carrier Proteins / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003424:Crohn Disease / Q000188:drug therapy*; D006207:Half-Life; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D013329:Structure-Activity Relationship; D016896:Treatment Outcome; D053319:Tumor Necrosis Factor Decoy Receptors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002352:Carrier Proteins; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D053319:Tumor Necrosis Factor Decoy Receptors; C069521:recombinant human tumor necrosis factor-binding protein-1